These results indicate that LCH with the BRAFN486_P490del mutation often affects multiple organs, has a high likelihood of disease reactivation, and shows a good response to MEK inhibitor treatment. This evidence concerns the gene MAP2K7 and Langerhans cell histiocytosis.